Rocket Pharmaceuticals, Inc. (RCKT) Operating income 2016–2025
Rocket Pharmaceuticals, Inc. (RCKT) annual operating income history from SEC filings — each fiscal year as reported.
-$231.7MFY2025 · since FY2016: -$7.6M → -$231.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$231.7M | +15.2% |
| FY2024 | -$273.2M | -5.2% |
| FY2023 | -$259.7M | -15.7% |
| FY2022 | -$224.3M | -34.1% |
| FY2021 | -$167.2M | -24.5% |
| FY2020 | -$134.3M | -76.4% |
| FY2019 | -$76.2M | -7.0% |
| FY2018 | -$71.2M | -259.9% |
| FY2017 | -$19.8M | -161.1% |
| FY2016 | -$7.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More RCKT financial trends
RCKT RevenueRCKT Net incomeRCKT Net marginRCKT Gross profitRCKT Gross marginRCKT Operating marginRCKT Operating cash flowRCKT Free cash flowRCKT Capital expendituresRCKT Return on equityRCKT Stock buybacksRCKT Dividends paidRCKT Total assetsRCKT Total liabilitiesRCKT Shareholders’ equityRCKT overview →